Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield Therapeutics notes UK launch of Feraccru® by Norgine

5 Dec 2018

Shield Therapeutics plc is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults. In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories. For full details please see the press release below:

Shield Therapeutics Press Release

To view the announcement released by Norgine, please click here.

 

 

Back to news